Cargando…

Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome

OBJECTIVES: To determine the frequency, severity and natural history of neutropaenia in early rheumatoid arthritis (RA), explore its associations with clinical features and assess its impact on clinical management. METHODS: The Scottish Early Rheumatoid Arthritis inception cohort prospectively recru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fragoulis, George E, Paterson, Caron, Gilmour, Ashley, Derakhshan, Mohammad H, McInnes, Iain B, Porter, Duncan, Siebert, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203094/ https://www.ncbi.nlm.nih.gov/pubmed/30402267 http://dx.doi.org/10.1136/rmdopen-2018-000739

Ejemplares similares

Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features
por: Fragoulis, George E, et al.
Publicado: (2020)

Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants
por: Siebert, Stefan, et al.
Publicado: (2016)

Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures
por: Kremer, Joel M, et al.
Publicado: (2016)

Is there room for better screening for lung cancer in rheumatoid arthritis?
por: Gialouri, Chrysoula G, et al.
Publicado: (2022)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Brief Report: Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients With Rheumatoid Arthritis
por: Ahmed, Ammad, et al.
Publicado: (2016)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Time-varying risks of infection in patients as they proceed through the phases of ‘pre-RA’: results from the Scottish Early RA inception cohort
por: Porter, Duncan, et al.
Publicado: (2023)

Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis
por: Kapoor, Sabrina R, et al.
Publicado: (2013)

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
por: Charles‐Schoeman, Christina, et al.
Publicado: (2019)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
por: Glatt, Sophie, et al.
Publicado: (2019)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib,
por: Charles‐Schoeman, Christina, et al.
Publicado: (2015)

Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody: Long‐Term Safety and Efficacy in Patients With Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2018)

Frailty in rheumatoid arthritis and its relationship with disease activity, hospitalisation and mortality: a longitudinal analysis of the Scottish Early Rheumatoid Arthritis cohort and UK Biobank
por: Hanlon, Peter, et al.
Publicado: (2022)

TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors
por: Ansalone, Cecilia, et al.
Publicado: (2021)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

How do multiple long-term conditions impact on the cost-of-illness in early rheumatoid arthritis?
por: Hsieh, Ping-Hsuan, et al.
Publicado: (2022)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIR‐1+CD8+ T Cells
por: Rothe, Kathrin, et al.
Publicado: (2016)

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
por: Taylor, Peter C, et al.
Publicado: (2023)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Management of Fatigue in Rheumatoid Arthritis
por: Pope, Janet E
Publicado: (2020)

Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis: Implications for Understanding Preclinical Rheumatoid Arthritis
por: de Hair, MJH, et al.
Publicado: (2014)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

Don’t neglect nutrition in rheumatoid arthritis!
por: Cutolo, Maurizio, et al.
Publicado: (2018)

Rheumatoid arthritis prevention: any takers?
por: Falahee, Marie, et al.
Publicado: (2021)

Overtreatment in rheumatoid arthritis: are there reasons for concern?
por: Ferreira, Ricardo J O, et al.
Publicado: (2022)

Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment
por: Heckert, Sascha L, et al.
Publicado: (2023)

Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals
por: Kroese, Johanna M., et al.
Publicado: (2021)

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
por: Fleischmann, Roy M, et al.
Publicado: (2023)

Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis
por: Marrie, Ruth Ann, et al.
Publicado: (2018)

Robust analyses for radiographic progression in rheumatoid arthritis
por: Landewé, Robert, et al.
Publicado: (2023)

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Relationship between shift work and the onset of rheumatoid arthritis
por: Hedström, Anna Karin, et al.
Publicado: (2017)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Subfertility in Women With Rheumatoid Arthritis and the Outcome of Fertility Assessments
por: Brouwer, Jenny, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_52ionf8ig2oooa44id0d6q1hrk